To determine whether the miR-146a downregulation and COX2 upregulation observed in BRAF/MEKi-resistant melanoma cell lines in vitro also occurred in vivo in melanoma patients, we analyzed tumor samples surgically excised for local treatment from patients undergoing BRAF/MEKi therapy. This evidence concerns the gene PTGS2 and melanoma.